Core Viewpoint - Reborn Bio-B (06938) has seen a stock increase of over 5%, currently trading at 72.45 HKD, following the announcement of its RBD5044 injection receiving implied approval for Phase II clinical trials from the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - The small nucleic acid drug sector is experiencing significant global growth, transitioning from technology validation to accelerated clinical realization and commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically, the number of research pipelines ranks second only to the United States, addressing multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Notable collaborations include over 9 billion USD in cumulative partnerships between WuXi AppTec and Novartis, and a 2 billion USD platform licensing deal between Reborn Bio and Boehringer Ingelheim [1] - Traditional pharmaceutical companies like China National Pharmaceutical Group are rapidly positioning themselves through acquisitions, indicating a positive development trend in the industry [1]

Core Viewpoint - Reborn Bio-B (06938) shares rose over 5%, currently up 5.62% at HKD 72.45, with a trading volume of HKD 6.483 million, following the announcement of the II phase clinical trial approval for its self-developed RBD5044 injection by the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - According to Guosheng Securities (002670), small nucleic acid drugs are entering a robust global development phase, transitioning from technical validation to clinical realization and accelerated commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically yet, the number of research pipelines ranks second to the U.S., covering multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Significant collaborations have emerged, such as the over USD 9 billion partnership between WuXi AppTec and Novartis, and a USD 2 billion platform licensing deal between Reborn Bio and Boehringer Ingelheim, indicating a positive development trend in the industry [1]

Core Insights - Longhua Technology (联化科技) is positioned as a leading player in the agricultural and pharmaceutical CDMO sectors, with significant achievements in small nucleic acid CDMO and potential in functional chemicals [1][2] Business Overview - Longhua Technology has established a collaborative development framework across four core industrial segments: agricultural protection, pharmaceuticals, functional chemicals, and equipment & engineering services [2] - The agricultural protection segment generated revenue of 1.702 billion yuan in the first half of 2025, with a gross margin increase of 9.48% year-on-year [2] - The pharmaceutical segment, focusing on APIs and intermediates, achieved revenue of 1.018 billion yuan in the first half of 2025, reflecting a year-on-year growth of 42.80% [2] Small Nucleic Acid CDMO - The company is leveraging small nucleic acid CDMO to tap into new growth opportunities, with advantages over traditional small molecule and antibody drugs, including broader target selection and higher success rates [3] - Since 2022, the market for small nucleic acid drugs has seen significant activity, with 32 transactions totaling 29.022 billion USD in 2025, indicating strong commercial value [3] - Longhua Technology has developed scalable production processes for modified nucleotides and has established a high-efficiency delivery system for nucleic acid drugs, enhancing its competitive edge [3] Functional Chemicals and Market Potential - The functional chemicals segment reported revenue of 0.265 billion yuan in the first half of 2025, marking a year-on-year doubling [4] - The company is focusing on lithium battery materials, including lithium hexafluorophosphate and LiFSI, with ongoing product development in various testing phases [4] - The National Development and Reform Commission's new storage action plan aims for over 1.8 million kilowatts by 2027, which is expected to drive significant market demand in the energy storage sector [4] Financial Performance - For the first three quarters of 2025, Longhua Technology reported total revenue of 4.718 billion yuan, an increase of 8.25% year-on-year, and a net profit of 316 million yuan, surging by 871.65% [1] - The projected net profit for 2025 is estimated to be between 350 million and 420 million yuan, representing a year-on-year growth of 239.35% to 307.22% [4]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The supply of raw materials in the pharmaceutical industry is accelerating, with a focus on subsequent price and volume changes [2] - The global GLP-1 market is evolving, with Chinese companies continuing to explore international opportunities [3] - Leading companies are gradually entering the small nucleic acid field, which is expected to drive the development of supporting industrial chains [4] - The retail pharmaceutical market is showing positive trends, with chain pharmacies enhancing their positioning [5] - The value of oral immunosuppressive drugs is gaining attention [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.47 percentage points in the last week, ranking 15th among 31 primary industry indices [18] - The pharmaceutical industry index increased by 0.14% during the same period [18] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 37.31, above the five-year historical average of 31.11 [40] 3. Recent Research Achievements - The report highlights various deep-dive studies on topics such as the growth of biological agents and oral medications, and the impact of policies on the inhalation drug industry [44] 4. Recent Industry Policies and News - The National Healthcare Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance sector [46] - Recent approvals for clinical trials of new drugs by major pharmaceutical companies, including AstraZeneca and Hengrui Medicine, indicate ongoing innovation in the industry [47][48] 5. Key Companies and Profit Forecasts - The report includes profit forecasts for several companies, with recommendations for stocks such as Yuyuan Pharmaceutical and Sunshine Nuohua, indicating a positive outlook for their performance [9]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry in China, indicating an expectation of returns exceeding the market benchmark by more than 5% [5]. Core Insights - Tirzepatide has been crowned the "King of Drugs," with annual sales reaching $36.507 billion in 2025, representing a 122% increase. It is expected to maintain its leading position for several years. Other notable drugs include Pembrolizumab with $31.7 billion in sales (+7%) and Semaglutide with approximately $34.606 billion (+18%) [9]. - The weight loss market is becoming a strategic focus for multinational corporations (MNCs), with significant investments and mergers and acquisitions (M&A) occurring in this sector. Major players are prioritizing weight loss in their strategies, with various drugs expected to enter clinical trials and receive approvals in 2026 [9]. - The demand for weight loss solutions is driving ongoing business development (BD) activities, with recent agreements indicating a robust pipeline for future innovations in this area [9]. - The commercial value of weight loss drugs is anticipated to be rapidly released, with MNCs viewing this sector as a core strategic area, leading to continued BD opportunities in oral small molecules, long-acting GLP-1s, and small nucleic acids [9]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include: - Genscript Biotech Corporation (01672, Buy) - Hengrui Medicine (600276, Buy) - Zhongsheng Pharmaceutical (002317, Buy) - Yuyuan Pharmaceutical (688658, Buy) - Shijiazhuang Pharmaceutical Group (01093, Not Rated) - Sunshine Novo Nordisk (688621, Buy) [9].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Insights - The company is positioned as a leading provider of chemical technology solutions, focusing on agricultural CDMO, pharmaceutical small molecules, and small nucleic acid CDMO, with significant achievements in functional chemicals [3][5]. - The agricultural sector is experiencing steady growth, while the pharmaceutical CDMO sector shows promising prospects, particularly in small nucleic acids, which are gaining traction in the market [6][7]. - The company is expanding its footprint in the new energy sector, particularly in lithium battery materials, which presents substantial growth potential [8]. Summary by Relevant Sections Company Overview - Founded in 1985 and located in Taizhou, Zhejiang Province, the company has evolved from producing flavor and fragrance intermediates to becoming a global custom manufacturing service provider in agriculture, pharmaceuticals, and functional chemicals [5][19]. - The company has established a comprehensive business platform that meets diverse customer needs across various stages of product development and lifecycle [21][24]. Agricultural Sector - The global agricultural industry is entering a mature phase, with projected sales of $77.2 billion in 2024, reflecting a 6.8% year-over-year decline. However, the sector is expected to expand steadily due to ongoing population growth [6][53]. - The competitive landscape is characterized by oligopolistic structures, with the top five companies holding a 57.4% market share in 2024, driven by innovation and strong brand channels [6][53]. Pharmaceutical CDMO - The company has been involved in small molecule CDMO for over a decade, with a robust revenue growth trajectory since 2017. A significant rebound is expected in 2025, with projected revenue of 1.018 billion yuan, a 42.8% increase year-over-year [7]. - The company is expanding into the small nucleic acid drug market, which is projected to see 32 transactions worth $29.022 billion in 2025, highlighting the growing commercial value of this segment [7]. Functional Chemicals - The lithium-ion battery electrolyte market is rapidly growing, with expected shipments reaching 2.235 million tons by 2025, a 46.4% increase. The company is focusing on lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide as key products in this sector [8][24]. - The company is well-positioned to capitalize on the increasing demand for lithium battery materials, with a focus on developing high-performance products [8]. Financial Performance - The company is expected to achieve net profits of 410 million, 630 million, and 790 million yuan for the years 2025 to 2027, respectively, indicating strong financial growth prospects [9].

Core Insights - The report from Dongfang Securities highlights the significant commercial value of extrahepatic delivery technology, driven by MNCs' increasing interest and the rapid development of domestic companies in multi-target drugs and extrahepatic delivery platforms [1][2][3] Group 1: Market Dynamics - Frequent transactions in small nucleic acids indicate rising global recognition of domestic drugs, exemplified by recent strategic collaborations involving Shengyin Biotech and major pharmaceutical companies like Eli Lilly and Roche, which include upfront payments and milestone payments totaling up to $12 billion and $15 billion respectively [1] - MNCs are shifting focus from liver-targeted delivery technologies to extrahepatic delivery systems, targeting organs such as fat, muscle, central nervous system, heart, and kidneys, which could address significant unmet clinical needs [2] Group 2: Domestic Innovation - Domestic companies have accumulated substantial experience in chemical modifications and liver-targeted delivery technologies for small nucleic acids, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [3] - The proactive development of extrahepatic delivery platforms and multi-target small nucleic acid drug platforms positions domestic firms at the forefront globally, attracting MNCs' interest [3] Group 3: Investment Opportunities - Potential investment targets include companies such as Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Chengdu Xian Dao, and others, which are positioned to benefit from the growing market for small nucleic acid drugs [4]

Group 1 - The company has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated LDL cholesterol [1][2] - BEBT-701 is developed using the proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, aiming to provide a comprehensive management solution for high cardiovascular risk populations through a single administration that simultaneously regulates blood pressure and lipid levels [2][3] - According to the World Health Organization, approximately 1.4 billion people globally suffer from hypertension, with around 245 million adults in China affected, highlighting the significant market potential for BEBT-701 in addressing cardiovascular diseases [3]

Core Viewpoint - The company, Bibet (688759.SH), has received approval from the National Medical Products Administration (NMPA) to conduct I-II phase clinical trials for its innovative siRNA drug, BEBT-701, aimed at treating mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol (LDL-C) levels [1][2]. Group 1: Company Developments - BEBT-701 is the first drug developed using the company's proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, designed to silence two key targets, angiotensinogen (AGT) and proprotein convertase subtilisin/kexin type 9 (PCSK9), simultaneously [1]. - The drug aims to provide a long-acting, low-frequency administration solution for managing chronic diseases, improving adherence among high cardiovascular risk populations [1]. Group 2: Clinical and Non-Clinical Research - Non-clinical studies have demonstrated that BEBT-701 achieves efficient and durable gene silencing of AGT and PCSK9 in humanized mouse models and non-human primates, showing synergistic effects in lowering blood pressure and cholesterol levels with good safety profiles [1]. - The World Health Organization's Global Hypertension Report indicates that approximately 1.4 billion people worldwide suffer from hypertension, with around 245 million adults affected in China, highlighting the significant market potential for effective treatments [2]. Group 3: Industry Context - The use of siRNA drugs, such as BEBT-701, represents a shift towards low-frequency, precise, and stable management of cardiovascular metabolic diseases, addressing issues related to long-term medication adherence and fluctuations in drug concentration [2].

Group 1 - The core viewpoint is that China's API (Active Pharmaceutical Ingredient) exports are expected to remain relatively stable in total volume by 2025, despite trade changes and price competition, reflecting the industry's competitiveness [1] - In 2026, uncertainties in API trade will persist, with further competition and cooperation between China and India [1] - New technologies, such as synthetic biology, are driving down unit costs and enhancing the global competitiveness of Chinese companies in terms of quality and service efficiency [1] Group 2 - Some API prices have already bottomed out, and the trend of supply clearing is expected to continue, potentially leading to a price rebound due to changes in the competitive landscape and capacity utilization rates [1] - China's innovative pharmaceutical sector is anticipated to see a strong start in 2026, with several significant licensing deals validating technological capabilities [1] - The clinical data in the small nucleic acid drug field continues to validate its potential, accelerating market progress and attracting more leading companies to invest, which may drive the development of the supporting industrial chain [1] Group 3 - In the GLP-1 (Glucagon-like peptide-1) sector, a new pricing system is forming domestically, with rapid growth in overseas oral formulations [1] - Oral autoimmune drugs are also showing significant value [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which focuses on new drug development driven by technological innovation, reflecting the overall trend of innovation in China's pharmaceutical industry [1]